Michael J Hanley

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 24

Top Topics

Tyrosine Kinase

Small Cell Lung Cancer

Acute Lymphoblastic Leukemia

Top Venues

CPT: pharmacometrics & systems pharmacology

Investigational new drugs

Clinical and translational science

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, D Ross Camidge, Robert J Fram, Neeraj Gupta
Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (3) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Jaydeep K Srimani, Paul Matthias Diderichsen, Michael J Hanley, Richard Labotka, Neeraj Gupta
Dose Titration of Ixazomib Maintenance Therapy in Transplant-Ineligible Multiple Myeloma: Exposure-Response Analysis of the TOURMALINE-MM4 Study. Clinical pharmacology and therapeutics (2023)
Michael J Hanley, Paul Matthias Diderichsen, Benjamin Rich, Anna Largajolli, Emilie Schindler, Alexander Vorog, Karthik Venkatakrishnan, Neeraj Gupta
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study. Clinical pharmacology and therapeutics (2023)
Neeraj Gupta, Michael J Hanley, Robert J Griffin, Pingkuan Zhang, Karthik Venkatakrishnan, Vikram Sinha
Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. Clinical pharmacokinetics (2023)
Michael J Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C Marbury, Karthik Venkatakrishnan, Neeraj Gupta
Brigatinib pharmacokinetics in patients with chronic hepatic impairment. Investigational new drugs (2023)
Neeraj Gupta, Karen L Reckamp, David R Camidge, Huub J Kleijn, Aziz Ouerdani, Francesco Bellanti, John Maringwa, Michael J Hanley, Shining Wang, Pingkuan Zhang, Karthik Venkatakrishnan
Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC. Clinical and translational science 15 (5) (2022)
Michael J Hanley, Manolo D'Arcangelo, Enriqueta Felip, Pilar Garrido, Jiaxi Zhu, Meng Ye, Florin Vranceanu, Neeraj Gupta
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors. Journal of clinical pharmacology (2022)
Neeraj Gupta, Philippe B Pierrillas, Michael J Hanley, Steven Zhang, Paul Matthias Diderichsen
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer. CPT: pharmacometrics & systems pharmacology 11 (6) (2022)
Neeraj Gupta, Michael J Hanley, Vikram Sinha
Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer. British journal of clinical pharmacology 88 (8) (2022)
Neeraj Gupta, Michael J Hanley, David Kerstein, Meera Tugnait, Narayana Narasimhan, Thomas C Marbury, Karthik Venkatakrishnan
Effect of severe renal impairment on the pharmacokinetics of brigatinib. Investigational new drugs 39 (5) (2021)
Michael J Hanley, Paul M Diderichsen, Narayana Narasimhan, Shouryadeep Srivastava, Neeraj Gupta, Karthik Venkatakrishnan
Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development. Journal of clinical pharmacology (2021)